Literature DB >> 29223429

Predicting risk of cardiac events among ST-segment elevation myocardial infarction patients with conservatively managed non-infarct-related artery coronary artery disease: An analysis of the Duke Databank for Cardiovascular Disease.

Sameer A Hirji1, Susanna R Stevens2, Linda K Shaw2, Erin C Campbell2, Christopher B Granger2, Manesh R Patel2, Michael H Sketch2, Tracy Y Wang2, E Magnus Ohman2, Eric D Peterson2, J Matthew Brennan3.   

Abstract

BACKGROUND: Recent randomized evidence has demonstrated benefit with complete revascularization during the index hospitalization for multivessel coronary artery disease ST-segment elevation myocardial infarction (STEMI) patients; however, this benefit likely depends on the risk of future major adverse cardiovascular events (MACE).
METHODS: Using data from Duke University Medical Center (2003-2012), we identified those at high risk for 1-year MACE among 664 STEMI patients with conservatively managed non-infarct-related artery (non-IRA) lesions. Using multivariable logistic regression, we identified clinical and angiographic characteristics associated with MACE (death, myocardial infarction, urgent revascularization) to 1 year and developed an integer-based risk prediction model for clinical use.
RESULTS: In this cohort (median age 60 years, 30% female), the unadjusted Kaplan-Meier rates for MACE at 30 days and 1 year were 10% and 28%, respectively. Characteristics associated with MACE at 1 year included reduced left ventricular ejection fraction, hypertension, heart failure, higher-risk non-IRA vessels (left main), renal insufficiency, and greater % stenosis of non-IRA lesions. A 15-point risk score including these variables had modest discrimination (C-index 0.67) across a spectrum of subsequent risk (4%-88%) for 1-year MACE.
CONCLUSIONS: There is a wide spectrum of risk following primary percutaneous coronary intervention for STEMI patients with multivessel disease. Using readily available clinical characteristics, the expected incidence of MACE by 1 year can be calculated with a simplified risk score, facilitating a tailored approach to clinical care.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2017        PMID: 29223429     DOI: 10.1016/j.ahj.2017.08.023

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  2 in total

Review 1.  Risks of restrictive red blood cell transfusion strategies in patients with cardiovascular disease (CVD): a meta-analysis.

Authors:  I Cortés-Puch; B M Wiley; J Sun; H G Klein; J Welsh; R L Danner; P Q Eichacker; C Natanson
Journal:  Transfus Med       Date:  2018-04-19       Impact factor: 2.019

2.  Baseline Serum sLOX-1 Concentrations Are Associated with 2-Year Major Adverse Cardiovascular and Cerebrovascular Events in Patients after Percutaneous Coronary Intervention.

Authors:  Zi-Wen Zhao; Yi-Wei Xu; Shu-Mei Li; Jin-Jian Guo; Jian-Min Sun; Ju-Chang Hong; Liang-Long Chen
Journal:  Dis Markers       Date:  2019-10-20       Impact factor: 3.434

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.